Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Kim Margolin, MD
Providence Saint John's Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Macquarie University Hospital
Macquarie Park, New South Wales, Australia
- Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
- Royal Adelaide Hospital
Adelaide, South Australia, Australia
- Olivia Newton-John Cancer Research Insititute
Heidelberg, Victoria, Australia
- Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
- University Hospitals Leuven
Leuven, Belgium
- Radboud University Medical Center
Nijmegen, Gelderland, Netherlands
- Leiden University Medical Center
Leiden, Netherlands
- Lausanne University Hospital
Lausanne, Switzerland
- Northern Centre for Cancer Care and Newcastle University
Newcastle upon Tyne, United Kingdom
- Carti Cancer Center
Little Rock, Arkansas, United States
- City of Hope
Duarte, California, United States
- Providence Saint John'S Cancer Institute
Santa Monica, California, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Ut Southwestern Medical Center
Dallas, Texas, United States
- University of Washington
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Dec 2021
- Primary completion
- 31 Jul 2025
- Completion
- 31 Jul 2025
- Last update posted
- 22 Jul 2024
- Registered enrollment
- 70
- Registry id
- NCT05013099
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.